Abstract
Background: Parkinson’s disease (PD) is the second most common neurological disorder characterized by loss of dopaminergic fibers in the basal ganglia and presence of Lewy bodies.
Method and Results: The literature suggests that caffeine plays multiple roles in PD. Epidemiological studies showed that caffeine intake was associated with less risk of developing PD, especially in genetically susceptible patients. On the level of Lewy bodies' formation, caffeine binds to α-synuclein protein inducing conformational changes and preventing their aggregation. On the level of mitochondrial stress, caffeine acts as an antioxidant that reduces oxidative stress in PD and therefore, slows the progression of the disease. On the level of dopamine release, the literature suggests that caffeine increases dopamine release and the number of dopamine receptors in the striatum via A2a receptor antagonism. Conclusion: As an adjuvant treatment, caffeine interacts with antiparkinsonian medications and can alter levodopa pharmacokinetics, reduce dyskinesia, and improve gait in patients with freezing of gait. In this review, we discussed the potential of caffeine as a possible neuroprotective agent and as an addon therapy for PD.Keywords: Adenosine receptors, Caffeine, Dopamine, Lewy bodies, Parkinson's disease, tremors.
CNS & Neurological Disorders - Drug Targets
Title:Caffeine; the Forgotten Potential for Parkinson's Disease
Volume: 16 Issue: 6
Author(s): Ahmed Negida*, Mohamed Elfil, Attia Attia, Eslam Farahat, Mohamed Gabr, Ahmed Essam, Doaa Attia and Hussein Ahmed
Affiliation:
- Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, Postal Code: 44519,Egypt
Keywords: Adenosine receptors, Caffeine, Dopamine, Lewy bodies, Parkinson's disease, tremors.
Abstract: Background: Parkinson’s disease (PD) is the second most common neurological disorder characterized by loss of dopaminergic fibers in the basal ganglia and presence of Lewy bodies.
Method and Results: The literature suggests that caffeine plays multiple roles in PD. Epidemiological studies showed that caffeine intake was associated with less risk of developing PD, especially in genetically susceptible patients. On the level of Lewy bodies' formation, caffeine binds to α-synuclein protein inducing conformational changes and preventing their aggregation. On the level of mitochondrial stress, caffeine acts as an antioxidant that reduces oxidative stress in PD and therefore, slows the progression of the disease. On the level of dopamine release, the literature suggests that caffeine increases dopamine release and the number of dopamine receptors in the striatum via A2a receptor antagonism. Conclusion: As an adjuvant treatment, caffeine interacts with antiparkinsonian medications and can alter levodopa pharmacokinetics, reduce dyskinesia, and improve gait in patients with freezing of gait. In this review, we discussed the potential of caffeine as a possible neuroprotective agent and as an addon therapy for PD.Export Options
About this article
Cite this article as:
Negida Ahmed*, Elfil Mohamed, Attia Attia, Farahat Eslam, Gabr Mohamed, Essam Ahmed, Attia Doaa and Ahmed Hussein, Caffeine; the Forgotten Potential for Parkinson's Disease, CNS & Neurological Disorders - Drug Targets 2017; 16 (6) . https://dx.doi.org/10.2174/1871527315666161107091149
DOI https://dx.doi.org/10.2174/1871527315666161107091149 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Current Pharmaceutical Biotechnology An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Amyloid-Binding Compounds and their Anti-Prion Potency
Current Topics in Medicinal Chemistry Inhibition of β-Amyloid Aggregation by Albiflorin, Aloeemodin and Neohesperidin and their Neuroprotective Effect on Primary Hippocampal Cells Against β-Amyloid Induced Toxicity
Current Alzheimer Research Basolateral Aggregated Rat Amyloidβ(1-42) Potentiates Transmigration of Primary Rat Monocytes through a Rat Blood-Brain Barrier
Current Neurovascular Research Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Multivariate Statistical Tools for the Evaluation of Proteomic 2D-maps:Recent Achievements and Applications
Current Proteomics From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B
Mini-Reviews in Medicinal Chemistry Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Resveratrol and Cancer: Chemoprevention, Apoptosis, and Chemoimmunosensitizing Activities
Current Medicinal Chemistry - Anti-Cancer Agents Bioinformatic Application in Proteomic Research on Biomarker Discovery and Drug Target Validation
Current Bioinformatics Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
Current Pharmaceutical Design Methamphetamine and HIV Infection, Role in Neurocognitive Dysfunction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry